Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Sophia Claire 2025 Sep 23, 16:10

Gold Price Surge: Analysis and Future Outlook Amidst Global Market Volatility

Ghko B 2025 Sep 23, 16:01

RIVN Stock Price Prediction: What will Rivian be worth in 2030?

stocks
Ghko B 2025 Sep 23, 16:00

Fintech Stocks to Watch Now: Nu Holdings (NU) Stock, SOFI Stock

stocks
Ghko B 2025 Sep 23, 16:00

Stock Market Today: Amazon (AMZN), Salesforce (CRM), Carrier Global (CARR)

stocks
Ghko B 2025 Sep 23, 16:00

Best CFD Brokers in the Middle East: markets.com, eToro, IC Markets

cfd trading
Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Liam James 2025 Sep 24, 06:20

Citigroup Exits Yield Curve Steepening Trade Amid Fed Independence Reassurance

Sophia Claire 2025 Sep 24, 04:20

Nvidia & OpenAI's $100B Bet: Innovation Catalyst or AI Bubble Inflator?

Emma Rose 2025 Sep 24, 03:20

Tether Eyes $20 Billion Funding Round: Potential $500 Billion Valuation

Emma Rose 2025 Sep 24, 02:20

Trump Cancels Budget Meeting, Heightening Government Shutdown Risk

Liam James 2025 Sep 24, 01:20

Iran's Supreme Leader Rules Out Nuclear Talks with US, Citing 'Surrender'

Ava Grace 2025 Sep 23, 18:20

Fed's Powell Signals Slowing Growth, Rate Cut as Inflation Remains Elevated

Ava Grace 2025 Sep 23, 15:20

US Interest Rate Volatility Plunge Squeezes Popular QIS Strategies

Sophia Claire 2025 Sep 23, 14:20

Fed's Bowman Warns of Falling Behind on Labor Market Support, Signals Faster Rate Cuts

Info

Spread

0.8317

Spread (%)

0.8469 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

23732162560

Shares Outstanding

240398724

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.68

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Sep 23, 16:01

Learn CFD Trading with Examples: How to trade CFDs in the Middle East

CFD Trading
Ghko B 2025 Sep 23, 16:01

NIO Stock Is Rising: How to Start NIO Stock CFD Trading in Saudi Arabia?

Stocks
Ghko B 2025 Sep 23, 16:00

Commodity CFD Trading in KSA: How Does Commodity CFD Trading Work?

Commodities CFD Trading
Trustpilot